Upcoming event
From October 15 to October 19, Radboud translational medicine will attend the 29th annual congress of the European Association of Nuclear Medicine.
Visit us at booth #59!
- Interesting? Share this article
Other news
1st production QuiremSpheres
On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the s...
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...
First Patient Dosed with TLX250-CDx in Italy for ccRCC
The below product is manufactured at RTM First Patient dosed with TLX250-CDx in Italy for ccRCC Th...
Interested in a collaboration?
Contact us to discuss the possibilities.